Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 35,400 shares, a growth of 6.9% from the November 15th total of 33,100 shares. Based on an average daily volume of 39,100 shares, the days-to-cover ratio is currently 0.9 days.

Insider Transactions at Benitec Biopharma

In other news, Director Suvretta Capital Management, L acquired 42,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average price of $9.60 per share, with a total value of $403,200.00. Following the completion of the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at $76,390,704. This trade represents a 0.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,102 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in Benitec Biopharma in the 3rd quarter valued at about $274,000. Simplify Asset Management Inc. bought a new position in Benitec Biopharma in the second quarter worth approximately $358,000. Geode Capital Management LLC grew its stake in Benitec Biopharma by 31.3% in the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after acquiring an additional 20,012 shares during the period. Finally, Nantahala Capital Management LLC bought a new stake in shares of Benitec Biopharma during the second quarter valued at approximately $5,881,000. 52.19% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BNTC. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Guggenheim reissued a “buy” rating and set a $17.00 price target on shares of Benitec Biopharma in a report on Tuesday, December 3rd. JMP Securities raised their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research note on Monday, October 14th. HC Wainwright initiated coverage on Benitec Biopharma in a research note on Monday. They set a “buy” rating and a $28.00 target price for the company. Finally, Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Price Performance

BNTC traded down $0.16 on Tuesday, reaching $12.42. The stock had a trading volume of 15,687 shares, compared to its average volume of 45,964. The firm has a 50-day moving average of $10.61 and a 200-day moving average of $9.32. Benitec Biopharma has a fifty-two week low of $2.69 and a fifty-two week high of $13.22.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.